A novel oral dual amylin and calcitonin receptor agonist (KBP-042) exerts antiobesity and antidiabetic effects in rats

American Journal of Physiology - Endocrinology and Metabolism

Volumn 307, Issue 1, 2014, Pages

  Andreassen, Kim V ^a   Feigh, Michael ^a,b   Hjuler, Sara T ^a   Gydesen, Sofie ^a   Henriksen, Jan Erik ^b   Beck Nielsen, Henning ^b   Christiansen, Claus ^a   Karsdal, Morten A ^a   Henriksen, Kim ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Amylin receptor; Blood glucose; Calcitonin receptor; Dual amylin and calcitonin receptor agonist; Insulin sensitivity; Type 2 diabetes; Weight loss

Indexed keywords

AMYLIN RECEPTOR; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CALCITONIN RECEPTOR; GLUCAGON; GLUCOSE; HORMONE RECEPTOR STIMULATING AGENT; INSULIN; KBP 042; N (5 CHLOROSALICYLOLYL) 8 AMINOCAPRYLIC ACID; OCTANOIC ACID; SALCATONIN; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; ANTIOBESITY AGENT; GLUCOSE BLOOD LEVEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ANTIOBESITY ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DIET; DRUG ACTIVITY; DRUG BINDING; EX VIVO STUDY; FOOD INTAKE; GLUCAGON RELEASE; GLUCOSE HOMEOSTASIS; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLEPTINEMIA; IMPAIRED GLUCOSE TOLERANCE; IN VITRO STUDY; INSULIN RELEASE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; MALE; NONHUMAN; PANCREAS ISLET; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; WEIGHT REDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; INSULIN RESISTANCE; ORAL DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT; TREATMENT OUTCOME; ZUCKER RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTI-OBESITY AGENTS; BLOOD GLUCOSE; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; RATS; RATS, SPRAGUE-DAWLEY; RATS, ZUCKER; RECEPTORS, CALCITONIN; RECEPTORS, ISLET AMYLOID POLYPEPTIDE; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84903582705     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00121.2014     Document Type: Article

References (46)

1. Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, Evans RM. PPARgamma signaling and metabolism: the good, the bad and the future. Nat Med 19: 557-566, 2013.
2. Akesson B, Panagiotidis G, Westermark P, Lundquist I. Islet amyloid polypeptide inhibits glucagon release and exerts a dual action on insulin release from isolated islets. Regul Pept 111: 55-60, 2003.
3. Akinmokun A, Selby PL, Ramaiya K, Alberti KG. The short insulin tolerance test for determination of insulin sensitivity: a comparison with the euglycaemic clamp. Diabet Med 9: 432-437, 1992.
4. Albrandt K, Mull E, Brady EM, Herich J, Moore CX, Beaumont K. Molecular cloning of two receptors from rat brain with high affinity for salmon calcitonin. FEBS Lett 325: 225-232, 1993.
5. Alwmark A, Stavinoha MW, Cooper CW, Greeley GH Jr, Thompson JC. Calcitonin inhibition of insulin release from isolated rat pancreatic islets. Diabetes 35: 58-60, 1986.
6. Brain SD, Grant AD. Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol Rev 84: 903-934, 2004.
7. Buse JB, Nauck M, Forst T, Sheu WH, Shenouda SK, Heilmann CR, Hoogwerf BJ, Gao A, Boardman MK, Fineman M, Porter L, Schernthaner G. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet 381: 117-124, 2013.
8. Cacho J, Sevillano J, de Castro J, Herrera E, Ramos MP. Validation of simple indexes to assess insulin sensitivity during pregnancy in Wistar and Sprague-Dawley rats. Am J Physiol Endocrinol Metab 295: E1269-E1276, 2008.
9. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 17: 819-837, 2013.
10. Christopoulos G, Perry KJ, Morfis M, Tilakaratne N, Gao Y, Fraser NJ, Main MJ, Foord SM, Sexton PM. Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Mol Pharmacol 56: 235-242, 1999.
11. Corkey BE. Banting lecture 2011: hyperinsulinemia: cause or consequence? Diabetes 61: 4-13, 2012.
12. Dunican KC, Adams NM, Desilets AR. The role of pramlintide for weight loss. Ann Pharmacother 44: 538-545, 2010.
13. Dunning BE, Gerich JE. The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Rev 28: 253-283, 2007.
14. Feigh M, Andreassen KV, Neutzsky-Wulff AV, Petersen ST, Hansen C, Bay-Jensen AC, Henriksen JE, Beck-Nielsen H, Christiansen C, Henriksen K, Karsdal MA. Oral salmon calcitonin attenuates hyperglycaemia and preserves pancreatic beta-cell area and function in Zucker diabetic fatty rats. Br J Pharmacol 167: 151-163, 2012.
15. Feigh M, Henriksen K, Andreassen KV, Hansen C, Henriksen JE, Beck-Nielsen H, Christiansen C, Karsdal MA. A novel oral form of salmon calcitonin improves glucose homeostasis and reduces body weight in diet-induced obese rats. Diabetes Obes Metab 13: 911-920, 2011.
16. Feigh M, Nielsen RH, Hansen C, Henriksen K, Christiansen C, Karsdal MA. Oral salmon calcitonin improves fasting and postprandial glycemic control in lean healthy rats. Horm Metab Res 44: 130-134, 2012.
17. Garber AJ. Novel GLP-1 receptor agonists for diabetes. Expert Opin Investig Drugs 21: 45-57, 2012.
18. Goldstein BJ. Insulin resistance as the core defect in type 2 diabetes mellitus. Am J Cardiol 90: 3G-10G, 2002.
19. Gotoh M, Maki T, Kiyoizumi T, Satomi S, Monaco AP. An improved method for isolation of mouse pancreatic islets. Transplantation 40: 437-438, 1985.
20. Hilton JM, Dowton M, Houssami S, Sexton PM. Identification of key components in the irreversibility of salmon calcitonin binding to calcitonin receptors. J Endocrinol 166: 213-226, 2000.
21. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444: 840-846, 2006.
22. Karsdal MA, Henriksen K, Bay-Jensen AC, Molloy B, Arnold M, John MR, Byrjalsen I, Azria M, Riis BJ, Qvist P, Christiansen C. Lessons learned from the development of oral calcitonin: the first tablet formulation of a protein in phase III clinical trials. J Clin Pharmacol 51: 460-471, 2011.
23. Kusakabe T, Ebihara K, Sakai T, Miyamoto L, Aotani D, Yamamoto Y, Yamamoto-Kataoka S, Aizawa-Abe M, Fujikura J, Hosoda K, Nakao K. Amylin improves the effect of leptin on insulin sensitivity in leptin-resistant diet-induced obese mice. Am J Physiol Endocrinol Metab 302: E924-E931, 2012.
24. Lamontagne J, Jalbert-Arsenault E, Pepin E, Peyot ML, Ruderman NB, Nolan CJ, Joly E, Madiraju SR, Poitout V, Prentki M. Pioglitazone acutely reduces energy metabolism and insulin secretion in rats. Diabetes 62: 2122-2129, 2013.
25. Lamontagne J, Pepin E, Peyot ML, Joly E, Ruderman NB, Poitout V, Madiraju SR, Nolan CJ, Prentki M. Pioglitazone acutely reduces insulin secretion and causes metabolic deceleration of the pancreatic beta-cell at submaximal glucose concentrations. Endocrinology 150: 3465-3474, 2009.
26. Lee S, Muniyappa R, Yan X, Chen H, Yue LQ, Hong EG, Kim JK, Quon MJ. Comparison between surrogate indexes of insulin sensitivity and resistance and hyperinsulinemic euglycemic clamp estimates in mice. Am J Physiol Endocrinol Metab 294: E261-E270, 2008.
27. Leinung MC, Grasso P. [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, augments the effects of orally delivered exenatide and pramlintide acetate on energy balance and glycemic control in insulinresistant male C57BLK/6-m db/db mice. Regul Pept 179: 33-38, 2012.
28. Leiter EH, Coleman DL, Eisenstein AB, Strack I. Dietary control of pathogenesis in C57BL/KsJ db/db diabetes mice. Metabolism 30: 554-562, 1981.
29. Levin BE, Dunn-Meynell AA, Balkan B, Keesey RE. Selective breeding for diet-induced obesity and resistance in Sprague-Dawley rats. Am J Physiol Regul Integr Comp Physiol 273: R725-R730, 1997.
30. Lutz TA. Control of energy homeostasis by amylin. Cell Mol Life Sci 69: 1947-1965, 2012.
31. Lutz TA, Mollet A, Rushing PA, Riediger T, Scharrer E. The anorectic effect of a chronic peripheral infusion of amylin is abolished in area postrema/nucleus of the solitary tract (AP/NTS) lesioned rats. Int J Obes Relat Metab Disord 25: 1005-1011, 2001.
32. Lutz TA, Tschudy S, Rushing PA, Scharrer E. Amylin receptors mediate the anorectic action of salmon calcitonin (sCT). Peptides 21: 233-238, 2000.
33. Mack CM, Smith PA, Athanacio JR, Xu K, Wilson JK, Reynolds JM, Jodka CM, Lu MG, Parkes DG. Glucoregulatory effects and prolonged duration of action of davalintide: a novel amylinomimetic peptide. Diabetes Obes Metab 13: 1105-1113, 2011.
34. Mack CM, Soares CJ, Wilson JK, Athanacio JR, Turek VF, Trevaskis JL, Roth JD, Smith PA, Gedulin B, Jodka CM, Roland BL, Adams SH, Lwin A, Herich J, Laugero KD, Vu C, Pittner R, Paterniti JR Jr, Hanley M, Ghosh S, Parkes DG. Davalintide (AC2307), a novel amylinmimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight. Int J Obes (Lond) 34: 385-395, 2010.
35. Mather K. Surrogate measures of insulin resistance: of rats, mice, and men. Am J Physiol Endocrinol Metab 296: E398-E399, 2009.
36. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and betacell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419, 1985.
37. Osaka T, Tsukamoto A, Koyama Y, Inoue S. Central and peripheral administration of amylin induces energy expenditure in anesthetized rats. Peptides 29: 1028-1035, 2008.
38. Prentki M, Nolan CJ. Islet beta cell failure in type 2 diabetes. J Clin Invest 116: 1802-1812, 2006.
39. Ryan G, Briscoe TA, Jobe L. Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes. Drug Des Devel Ther 2: 203-214, 2009.
40. Shiota M, Printz RL. Diabetes in Zucker diabetic fatty rat. Methods Mol Biol 933: 103-123, 2012.
41. Silvestre RA, Rodriguez-Gallardo J, Jodka C, Parkes DG, Pittner RA, Young AA, Marco J. Selective amylin inhibition of the glucagon response to arginine is extrinsic to the pancreas. Am J Physiol Endocrinol Metab 280: E443-E449, 2001.
42. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC. Measurement of protein using bicinchoninic acid. Anal Biochem 150: 76-85, 1985.
43. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: pathogenesis and treatment. Lancet 371: 2153-2156, 2008.
44. Tanaka H, Kashiwagi R, Koizumi T. Inhibition of calcitonin generelated peptide (CGRP) has the potential to extend first-phase insulin secretion. Exp Clin Endocrinol Diabetes 121: 280-285, 2013.
45. Traina AN, Kane MP. Primer on pramlintide, an amylin analog. Diabetes Educ 37: 426-431, 2011.
46. Wielinga PY, Alder B, Lutz TA. The acute effect of amylin and salmon calcitonin on energy expenditure. Physiol Behav 91: 212-217, 2007.